Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 77,862
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12569430 | Biodegradable implant including naltrexone | 🖼🧊📄§ | 2026-03-10 | 2042-04-01 | 0 | 31 |
| 12569495 | Inhibitors of porcine reproductive and respiratory syndrome virus | 🖼🧊📄§ | 2026-03-10 | 2041-05-28 | 0 | 31 |
| 12569512 | Heparan sulfate (HS) oligosaccharides effect in liver ischemia reperfusion injury | 🖼🧊📄§ | 2026-03-10 | 2042-05-13 | 0 | 31 |
| 12570980 | Methods and compositions for treating inflammatory conditions associated with infectious disease | 🖼🧊📄§ | 2026-03-10 | 2045-04-02 | 0 | 31 |
| 12569482 | Methods and compositions for treating idiopathic pulmonary fibrosis | 🖼🧊📄§ | 2026-03-10 | 2040-10-02 | 0 | 31 |
| 12569524 | Compositions and methods for preventing and treating antibiotic induced pathologies using probiotics in the biofilm state | 🖼🧊📄§ | 2026-03-10 | 2039-10-21 | 0 | 31 |
| 12569484 | Use of phosphodiesterase 5 inhibitor in preparation of medicament for resisting fibrotic diseases | 🖼🧊📄§ | 2026-03-10 | 2040-07-29 | 0 | 31 |
| 12571027 | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF | 🖼🧊📄§ | 2026-03-10 | 2044-09-10 | 0 | 31 |
| 12569491 | Methods for treating testicular and ovarian adrenal rest tumors | 🖼🧊📄§ | 2026-03-10 | 2045-01-31 | 0 | 31 |
| 12569543 | Semaglutide in cardiovascular conditions | 🖼🧊📄§ | 2026-03-10 | 2037-04-28 | 0 | 31 |
| 12569556 | Aluminum based adjuvants for tolerogenic vaccination | 🖼🧊📄§ | 2026-03-10 | 2041-01-29 | 0 | 31 |
| 12570670 | Compounds, compositions, and methods for treating fibrosis | 🖼🧊📄§ | 2026-03-10 | 2040-01-30 | 0 | 31 |
| 12570686 | Chemical structures that control metabolic elimination of aminosterols | 🖼🧊📄§ | 2026-03-10 | 2045-02-18 | 0 | 31 |
| 12570728 | Combinations of antibodies and bispecific antibodies comprising antigen-binding specifically recognizing Pseudomonas PcrV and Psl | 🖼🧊📄§ | 2026-03-10 | 2041-11-18 | 0 | 31 |
| 12569048 | Method for removing hair from an area of skin | 🖼🧊📄§ | 2026-03-10 | 2043-10-24 | 0 | 31 |
| 12570733 | Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules | 🖼🧊📄§ | 2026-03-10 | 2042-06-30 | 0 | 31 |
| 12570744 | Bispecific PD-1 and TIGIT binding proteins and uses thereof | 🖼🧊📄§ | 2026-03-10 | 2044-02-14 | 0 | 31 |
| 12570622 | Therapeutic compounds | 🖼🧊📄§ | 2026-03-10 | 2042-11-29 | 0 | 31 |
| 12570614 | Phenyl amino pyrimidine compounds and uses thereof | 🖼🧊📄§ | 2026-03-10 | 2042-04-20 | 0 | 31 |
| 12570628 | Salts of obicetrapib and processes for their manufacture and intermediates thereof | 🖼🧊📄§ | 2026-03-10 | 2045-04-14 | 0 | 31 |
| 12569442 | Process for producing a pharmaceutical formulation comprising active substance, polymer and surfactant | 🖼🧊📄§ | 2026-03-10 | 2040-10-05 | 0 | 31 |
| 12569410 | Photocurable composition and dental product | 🖼🧊📄§ | 2026-03-10 | 2040-10-28 | 0 | 31 |
| 12569183 | Method of administering sotalol IV/switch | 🖼🧊📄§ | 2026-03-10 | 2043-01-18 | 0 | 31 |
| 12569435 | Ocular compositions and methods thereof | 🖼🧊📄§ | 2026-03-10 | 2043-02-21 | 0 | 31 |
| 12569555 | Organically modified mineral micro-particles, methods of preparing the same and uses thereof | 🖼🧊📄§ | 2026-03-10 | 2039-04-10 | 0 | 31 |
| 12569619 | Techniques for determining automated insulin delivery dosages | 🖼🧊📄§ | 2026-03-10 | 2040-09-21 | 0 | 31 |
| 12569444 | System and method for isolating extracellular vesicles | 🖼🧊📄§ | 2026-03-10 | 2041-04-23 | 0 | 31 |
| 12571587 | Finishing apparatus for a spray drying system | 🖼🧊📄§ | 2026-03-10 | 2043-09-14 | 0 | 31 |
| 12569576 | Compositions and methods for measuring oxidative stress | 🖼🧊📄§ | 2026-03-10 | 2041-06-10 | 0 | 31 |
| 12569513 | Stable, highly pure L-cysteine compositions for injection and methods of use | 🖼🧊📄§ | 2026-03-10 | 2044-12-24 | 0 | 31 |
| 12565526 | Formulations of anti-RSV antibodies and methods of use thereof | 🖼🧊📄§ | 2026-03-03 | 2039-10-14 | 0 | 31 |
| 12564739 | Engineered natural killer (NK) cells and compositions and methods thereof | 🖼🧊📄§ | 2026-03-03 | 2044-01-31 | 0 | 31 |
| 12564566 | Uses of long-chain polyunsaturated fatty acids | 🖼🧊📄§ | 2026-03-03 | 2040-08-07 | 0 | 31 |
| 12565521 | Systems, kits, and methods for forming in situ silk fibroin fibers and/or aerosols | 🖼🧊📄§ | 2026-03-03 | 2043-11-03 | 0 | 31 |
| 12565535 | Chimeric antigen receptors targeted to PSCA | 🖼🧊📄§ | 2026-03-03 | 2042-08-17 | 0 | 31 |
| 12564638 | EGFR protein degradant and anti-tumor application thereof | 🖼🧊📄§ | 2026-03-03 | 2040-08-05 | 0 | 31 |
| 12564630 | Vaccine adjuvants | 🖼🧊📄§ | 2026-03-03 | 2041-05-04 | 0 | 31 |
| 12564621 | Interleukin-18 variants and methods of use | 🖼🧊📄§ | 2026-03-03 | 2043-11-03 | 0 | 31 |
| 12564549 | Cleanser composition | 🖼🧊📄§ | 2026-03-03 | 2041-03-26 | 0 | 31 |
| 12564557 | Dual release dosage form capsule and methods, devices and systems for making same | 🖼🧊📄§ | 2026-03-03 | 2044-04-02 | 0 | 31 |
| 12564583 | Small molecules against cereblon to enhance effector T cell function | 🖼🧊📄§ | 2026-03-03 | 2042-06-07 | 0 | 31 |
| 12564589 | Methods for treating cancer, reducing side effects of cancer treatment, and preventing the recurrence of cancer | 🖼🧊📄§ | 2026-03-03 | 2045-03-18 | 0 | 31 |
| 12564591 | HCK as a therapeutic target in MYD88 mutated diseases | 🖼🧊📄§ | 2026-03-03 | 2040-10-07 | 0 | 31 |
| 12565682 | Methods of treating cancer | 🖼🧊📄§ | 2026-03-03 | 2040-11-25 | 0 | 31 |
| 12565650 | STAUFEN1 regulating agents and associated methods | 🖼🧊📄§ | 2026-03-03 | 2044-04-01 | 0 | 31 |
| 12565518 | Hybrid cyclic libraries and screens thereof | 🖼🧊📄§ | 2026-03-03 | 2044-02-07 | 0 | 31 |
| 12565529 | Methods for treating type 1 diabetes | 🖼🧊📄§ | 2026-03-03 | 2042-05-24 | 0 | 31 |
| 12565530 | Combination therapy with targeted 4-1BB (CD137) agonists/anti-FAP binding domain and anti-CEA/anti-CD3 bispecific antibody | 🖼🧊📄§ | 2026-03-03 | 2043-02-09 | 0 | 31 |
| 12565532 | Monoclonal antibodies that bind EGFRvIII and their use | 🖼🧊📄§ | 2026-03-03 | 2040-07-01 | 0 | 31 |
| 12565538 | FCRN/antigen-binding molecules and methods of use | 🖼🧊📄§ | 2026-03-03 | 2045-07-01 | 0 | 31 |